GLP-1 receptor agonist
Dulaglutide
Answer
Dulaglutide is authorised or registered in the US, the EU, the UK, Canada, Australia, Switzerland, Brazil, Serbia, Singapore and Turkey: 10 of the 10 registers read. Highest trial phase: Phase 4 (after approval). It has 144 registered trials, 23 of them running. Brand names on the FDA label register: Trulicity.
RegulatorTrial register10 regulators' registers, read 2026-09-03 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
144 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 45 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 43 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Authorised | EMA, ema | 2026-10-03 |
| United Kingdom | Authorised | MHRA, uk-mhra | 2026-10-03 |
| Canada | Authorised | Health Canada, ca-dpd | 2026-10-03 |
| Australia | Registered | TGA, au-artg | 2026-10-03 |
| Switzerland | Authorised | Swissmedic, ch-swissmedic | 2026-10-03 |
| Brazil | Registado | ANVISA, br-anvisa | 2026-10-03 |
| Serbia | Authorised | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Registered | HSA, sg-hsa | 2026-09-03 |
| Turkey | Ruhsatli | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
Side effects
Trial registerCHANGE ALERTS
Get an email when this changes
One email when the status of Dulaglutide changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 144 trials
| NCT07668336 | A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes not yet recruiting participants · register updated 2026-09-25 |
|---|---|
| 2025-524811-35-00 | J2A-MC-GZGY: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral no status recorded · register updated 2026-09-24 |
| NCT07834398 | Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes completed · register updated 2026-09-22 |
| NCT06779929 | Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants W completed · register updated 2026-09-18 |
| NCT07820111 | Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial completed · register updated 2026-09-15 |
| NCT06851962 | Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. completed · register updated 2026-09-04 |
| NCT07787936 | GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry not yet recruiting participants · register updated 2026-08-26 |
| NCT07313813 | A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants Wi completed · register updated 2026-08-21 |
| NCT05220917 | Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study running, but no longer enrolling · register updated 2026-08-13 |
| NCT05478707 | Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes currently recruiting participants · register updated 2026-08-12 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.